The multidisciplinary management of functioning pituitary tumours, including prolactin, growth hormone (GH)- or adrenocorticotropic hormone (ACTH)-secreting tumours, is crucial for improving clinical outcomes and the prognosis of patients [22,23,44,45,46,47,48]. The gene discussed is GH1; the disease is neoplasm.